-
Mashup Score: 20
Here, we summarize a publication by Mohty et al. in the British Journal of Haematology on patient-reported outcomes following treatment with elranatamab in the phase II MagnetisMM-3 clinical trial.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
During the Multiple Myeloma Hub virtual symposium held on March 11, 2024, “Current and future perspectives for bispecific antibodies in multiple myeloma: Lea…
Source: www.youtube.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
On March 11, 2024, the Multiple Myeloma Hub hosted a virtual symposium, “Current and future perspectives for bispecific antibodies in multiple myeloma: Learn…
Source: www.youtube.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5
Here, we summarize a subanalysis by Oriol et al. published in Clinical Lymphoma, Myeloma and Leukemia on the results of the OPTIMISMM trial by frailty status and bortezomib dose adjustment.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 40
The Multiple Myeloma Hub virtual symposium was chaired by Sagar Lonial, and featured expert presentations from Naresh Bumma, Amrita Krishnan, and Sergio Giralt.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 13Infections following bispecific antibody therapy in MM: incidence and characteristics - 25 day(s) ago
Here, we summarize a multicenter, retrospective study conducted in France on the incidence and characteristics of infections following treatment with bispecific antibody therapy.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4
Here, we summarize a publication by Murugappan, et al. in Journal of Geriatric Oncology on a comparison between approaches to measuring frailty: the patient-reported frailty phenotype (PRFP) and the International Myeloma Working Group Frailty Index (IMWG FI).
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 41
The Multiple Myeloma Hub virtual symposium was chaired by Sagar Lonial, and featured expert presentations from Naresh Bumma, Amrita Krishnan, and Sergio Giralt.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5FDA approves idecabtagene vicleucel for triple-class-exposed RRMM - 1 month(s) ago
On April 5, 2024, the U.S. FDA granted approval to idecabtagene vicleucel for the treatment of triple-class-exposed relapsed/refractory multiple myeloma after two or more prior therapies, including an immunomodulatory agent, proteasome inhibitor, and an anti-CD38 antibody.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2CAR T-cell therapy in older patients: Efficacy and rates of immune-mediated toxicity - 1 month(s) ago
We summarize a systematic review and meta-analysis by Akhtar et al. investigating the efficacy of CAR T-cell therapy and rates of immune-mediated toxicity in patients ≥65 years old with multiple myeloma.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
52.6% of BCMA-exposed patients treated with elranatamab in the MagnetisMM-3 trial described their pain score as a ‘little’ or ‘much’ better. Learn more about the patient-reported outcomes from MagnetisMM-3 here: https://t.co/m07hTfUWZq #mmsm #myeloma #MultipleMyeloma https://t.co/ugqSbejGnZ